Grid Therapeutics

About:

Grid develops an innovative platform to develop human derived antibodies focusing on cancer therapeutics.

Website: https://gridtherapeutics.com/

Twitter/X: gridthr

Top Investors: Milestone Holdings, Jeffery “TJ” Heyman, Longview International, Paul Funk

Description:

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients and was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is expected to enter a first-in-man Phase 1 clinical trial in advanced-stage solid tumor patients in early 2019.